Advisory Council for the Elimination of Tuberculosis (ACET), 8191-8192 [2014-02859]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 28 / Tuesday, February 11, 2014 / Notices
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2014–02937 Filed 2–10–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee to the Director
(ACD), Centers for Disease Control and
Prevention (CDC): Notice of Charter
Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the
Advisory Committee to the Director,
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS), has been
renewed for a 2-year period extending
through February 1, 2016.
Contact Person for More Information:
Carmen Villar, M.S.W., Designated
Federal Officer, Advisory Committee to
the Director, CDC, 1600 Clifton Road,
NE., Mailstop D14, Atlanta, Georgia
30333, Telephone 404–639–7000.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2014–02881 Filed 2–10–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
tkelley on DSK3SPTVN1PROD with NOTICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns NIOSH Member Conflict
Review, PA 07–318, initial review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
VerDate Mar<15>2010
17:58 Feb 10, 2014
Jkt 232001
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 1:00 p.m.–4:00 p.m., March
13, 2014 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘NIOSH Member Conflict
Review, PA 07–318.
Contact Person for More Information: Nina
Turner, Ph.D., Scientific Review Officer,
1095 Willowdale Road, Morgantown, WV
26506, Telephone: (304) 285–5976.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2014–02856 Filed 2–10–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns Reduction of Malaria in U.S.
Residents Returning from Overseas
Travel to Malaria-Endemic Countries,
FOA CK14–004, Initial Review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 12:00 p.m.–4:00 p.m.,
March 18, 2014 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Reduction of Malaria in U.S.
Residents Returning from Overseas Travel to
Malaria-Endemic Countries, FOA CK14–
004’’.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
8191
Contact Person for More Information:
Gregory Anderson, M.S., M.P.H., Scientific
Review Officer, CDC, 1600 Clifton Road NE.,
Mailstop E60, Atlanta, Georgia 30333,
Telephone: (404) 718–8833.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2014–02857 Filed 2–10–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Council for the Elimination of
Tuberculosis (ACET)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Time and Date: 11:00 a.m.–4:10 p.m.,
March 4, 2014.
Place: This meeting is accessible by Web
conference. Toll-free +1 (800) 857–9642,
Participant Code: 4131105
For Participants:
URL: https://www.mymeetings.com/nc/join/
Conference number: PW3964772
Audience passcode: 4131105
Participants can join the event directly at:
https://www.mymeetings.com/nc/join.php?i=
PW3964772&p=4131105&t=c
Status: Open to the public limited only by
web conference. Participation by web
conference is limited by the number of 100
ports available.
Purpose: This council advises and makes
recommendations to the Secretary of Health
and Human Services, the Assistant Secretary
for Health, and the Director, CDC, regarding
the elimination of tuberculosis. Specifically,
the Council makes recommendations
regarding policies, strategies, objectives, and
priorities; addresses the development and
application of new technologies; and reviews
the extent to which progress has been made
toward eliminating tuberculosis.
Matters To Be Discussed: Agenda items
include the following topics: (1) U.S.
Prevention Services Task Force and Medicaid
coverage for tuberculosis (TB); (2) Update on
CDC Global TB issues; (3) Updates from
Workgroups; and (4) other tuberculosisrelated issues.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Margie Scott-Cseh, Centers for Disease
E:\FR\FM\11FEN1.SGM
11FEN1
8192
Federal Register / Vol. 79, No. 28 / Tuesday, February 11, 2014 / Notices
Control and Prevention, 1600 Clifton Road
NE., M/S E–07, Atlanta, Georgia 30333,
telephone (404) 639–8317; Email: zkr7@
cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register Notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention (CDC).
[FR Doc. 2014–02859 Filed 2–10–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee
tkelley on DSK3SPTVN1PROD with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee:
Times and Dates:
8:30 a.m.–4:30 p.m., March 5, 2014
8:30 a.m.–12:00 p.m., March 6, 2014
Place: CDC, 1600 Clifton Road NE., Tom
Harkin Global Communications Center,
Building 19, Auditorium B, Atlanta, Georgia
30333. This meeting will also be Webcast,
please see information below.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 100 people.
Purpose: This Committee is charged with
providing scientific and technical advice and
guidance to the Secretary of Health and
Human Services (HHS); the Assistant
Secretary for Health; the Director, Centers for
Disease Control and Prevention; the
Commissioner, Food and Drug
Administration (FDA); and the
Administrator, Centers for Medicare and
Medicaid Services (CMS). The advice and
guidance pertain to general issues related to
improvement in clinical laboratory quality
and laboratory medicine practice and specific
questions related to possible revision of the
Clinical Laboratory Improvement
Amendment (CLIA) standards. Examples
include providing guidance on studies
designed to improve safety, effectiveness,
efficiency, timeliness, equity, and patientcenteredness of laboratory services; revisions
to the standards under which clinical
laboratories are regulated; the impact of
proposed revisions to the standards on
medical and laboratory practice; and the
modification of the standards and provision
of non-regulatory guidelines to accommodate
technological advances, such as new test
VerDate Mar<15>2010
17:58 Feb 10, 2014
Jkt 232001
methods and the electronic transmission of
laboratory information.
Matters To Be Discussed: The agenda will
include agency updates from CDC, CMS, and
FDA. Presentations and discussions will
include the CMS implementation of
Individualized Quality Control Plan (IQCP)
as a new CLIA quality control option based
on risk management for laboratories
performing nonwaived testing; CDC’s
strategic priority for strengthening public
health and health care collaborations; and
quality improvement tools for managing
laboratory testing in ambulatory settings.
Agenda items are subject to change as
priorities dictate.
Webcast: The meeting will also be
Webcast. Persons interested in viewing the
Webcast can access information at: https://
wwwn.cdc.gov/cliac/default.aspx.
Online Registration Required: All people
attending the CLIAC meeting in-person are
required to register for the meeting online at
least 5 business days in advance for U.S.
citizens and at least 10 business days in
advance for international registrants. Register
at https://wwwn.cdc.gov/cliac/default.aspx by
scrolling down and clicking the appropriate
link under ‘‘Meeting Registration’’ (either
U.S. Citizen Registration or Non-U.S. Citizen
Registration) and completing all forms
according to the instructions given. Please
complete all the required fields before
submitting your registration and submit no
later than February 26, 2014 for U.S.
registrants and February 19, 2014 for
international registrants.
Providing Oral or Written Comments: It is
the policy of CLIAC to accept written public
comments and provide a brief period for oral
public comments whenever possible. Oral
Comments: In general, each individual or
group requesting to make oral comments will
be limited to a total time of five minutes
(unless otherwise indicated). Speakers must
also submit their comments in writing for
inclusion in the meeting’s Summary Report.
To assure adequate time is scheduled for
public comments, speakers should notify the
contact person below at least one week prior
to the meeting date. Written Comments: For
individuals or groups unable to attend the
meeting, CLIAC accepts written comments
until the date of the meeting (unless
otherwise stated). However, it is requested
that comments be submitted at least one
week prior to the meeting date so that the
comments may be made available to the
Committee for their consideration and public
distribution. Written comments, one hard
copy with original signature, should be
provided to the contact person below, and
will be included in the meeting’s Summary
Report.
Availability of Meeting Materials: To
support the green initiatives of the federal
government, the CLIAC meeting materials
will be made available to the Committee and
the public in electronic format (PDF) on the
internet instead of by printed copy. Check
the CLIAC Web site on the day of the meeting
for materials. Note: If using a mobile device
to access the materials, please verify that the
device’s browser is able to download the files
from the CDC’s Web site before the meeting.
https://wwwn.cdc.gov/cliac/
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
cliac_meeting_all_documents.aspx
Alternatively, the files can be downloaded to
a computer and then emailed to the portable
device. An internet connection, power source
and limited hard copies may be available at
the meeting location, but cannot be
guaranteed.
Contact Person for Additional Information:
Nancy Anderson, Chief, Laboratory Practice
Standards Branch, Division of Laboratory
Programs, Standards, and Services, Center for
Surveillance, Epidemiology and Laboratory
Services, Office of Public Health Scientific
Services, Centers for Disease Control and
Prevention, 1600 Clifton Road NE., Mailstop
F–11, Atlanta, Georgia 30329–4018;
telephone (404) 498–2741; or via email at
NAnderson@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register Notices
pertaining to announcements of meetings and
other committee management activities, for
CDC and the Agency for Toxic Substances
and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2014–02858 Filed 2–10–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–0129]
Application of Physiologically-Based
Pharmacokinetic Modeling To Support
Dose Selection; Notice of Public
Workshop; Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice of public workshop;
request for comments.
ACTION:
The Food and Drug
Administration (FDA or the Agency) is
announcing a public workshop entitled
‘‘Application of Physiologically-Based
Pharmacokinetic (PBPK) Modeling to
Support Dose Selection.’’ The purpose
of the workshop is to obtain input on
scientific approaches for the conduct
and assessment of physiologically-based
pharmacokinetic (PBPK) modeling
within the framework of drug
development and regulatory
decisionmaking. The input from the
workshop may be used to refine FDA’s
thinking on the various applications of
PBPK. Preliminary elements of a draft
concept paper will be presented to
facilitate discussion at this public
workshop.
DATES: The workshop will be held on
March 10, 2014, from 8:30 a.m. to 4:30
p.m. Individuals who wish to attend the
SUMMARY:
E:\FR\FM\11FEN1.SGM
11FEN1
]]>Agencies
[Federal Register Volume 79, Number 28 (Tuesday, February 11, 2014)]
[Notices]
[Pages 8191-8192]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-02859]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Council for the Elimination of Tuberculosis (ACET)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting of the aforementioned
committee:
Time and Date: 11:00 a.m.-4:10 p.m., March 4, 2014.
Place: This meeting is accessible by Web conference. Toll-free
+1 (800) 857-9642, Participant Code: 4131105
For Participants:
URL: https://www.mymeetings.com/nc/join/
Conference number: PW3964772
Audience passcode: 4131105
Participants can join the event directly at: https://www.mymeetings.com/nc/join.php?i=PW3964772&p=4131105&t=c
Status: Open to the public limited only by web conference.
Participation by web conference is limited by the number of 100
ports available.
Purpose: This council advises and makes recommendations to the
Secretary of Health and Human Services, the Assistant Secretary for
Health, and the Director, CDC, regarding the elimination of
tuberculosis. Specifically, the Council makes recommendations
regarding policies, strategies, objectives, and priorities;
addresses the development and application of new technologies; and
reviews the extent to which progress has been made toward
eliminating tuberculosis.
Matters To Be Discussed: Agenda items include the following
topics: (1) U.S. Prevention Services Task Force and Medicaid
coverage for tuberculosis (TB); (2) Update on CDC Global TB issues;
(3) Updates from Workgroups; and (4) other tuberculosis-related
issues.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Margie Scott-Cseh, Centers
for Disease
[[Page 8192]]
Control and Prevention, 1600 Clifton Road NE., M/S E-07, Atlanta,
Georgia 30333, telephone (404) 639-8317; Email: zkr7@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention (CDC).
[FR Doc. 2014-02859 Filed 2-10-14; 8:45 am]
BILLING CODE 4163-18-P
